A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)

15923ABLE-22-NCT06545955OpenA Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)ABLE-22NCT06545955IndustrialAdultTreatmentIIUrinary BladderGupta, MohitGeorgetown University Medical Center : Jamie Manganti, Alan Zwart; Lombardi Comprehensive Cancer Center : Jamie Manganti, Alan ZwartGenito-urinaryOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS16795Alan ZwartAlan Zwartaz6@georgetown.edu16801Jamie MangantiJamie Mangantijm3821@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>